GLIOFIL

This technology has been patented since 2021 under the number EP3821396, extended in Australia, Canada, China, Japan and United-State and co-owned University of Caen, France, National Institute of Health and Medical Research, France, François Baclesse Regional Center, France and University of Vilnius, Lithuania.

Description:

The Gliofil project proposes new first-in-class peptides targeting a novel therapeutic target involved in glioblastoma malignancy. The peptides have been optimized for penetration and diffusion into tumor cells, and 2 lead candidates have been selected based on in vitro results. We have notably demonstrated that these peptides decrease the viability and chemotactic migration of several glioma cell lines, both alone and in combination with temozolomide (additive effect). Ex vivo, the peptides accumulate very rapidly in the tumor and quickly induce a decrease in cell density. In vivo, in an orthotopic xenograft model, the peptides significantly improve the median survival of animals treated via intranasal administration, while reducing tumor volume and infiltrates. These peptides represent a new therapeutic hope for patients with glioblastoma and potentially other metastatic solid cancers.

We are looking for a licensee or co-development deal.